I am writing to provide an update on progress with this study and to give details for those who may wish to become involved.
Earlier in May this year Richmond Pharmacology began recruiting patient volunteers with painful diabetic neuropathy to take part in a clinical trial of a new experimental drug called ABT-639.
ABT-639 is a ‘calcium channel blocker’ that is being developed for the treatment of diabetic peripheral neuropathy (damage to the nerves that connect the brain and spinal cord to the limbs and organs). Current medications for this condition are not always effective and sometimes have undesirable side effects. ABT-639 works differently and it is anticipated that it may work better and have fewer side effects.
With thanks to its respected volunteers Richmond Pharmacology have now dosed a total of 29 suitable candidates with painful diabetic neuropathy with a further 7 candidates due to attend a screening visit next week and 6 awaiting admission over the coming weeks.
Richmond Pharmacology is therefore looking for 7 or more suitable candidates to enrol into this study over the coming weeks on the basis that those already screened and seemingly suitable attend admission and are subsequently dosed into this study.
If you are interested in becoming involved and available to attend a screening visit (to determine your eligibility), this week or next for possible inclusion next week or the week after, please:
Call the Trials4Patients team on +44 (0) 20 8664 5200 (choose option 1) and ask to speak to Myster or Natasha (Mon-Fri 9am-5pm)